Heart Failure: Improving Implementation of Advanced Guideline-Recommended Therapies
Submission Deadline: 17th September 2023We are pleased to offer a 25% discount on the Article Processing Charge (APC) for articles submitted to this Special Issue. Please visit our author hub for more information about the benefits of submitting to a Special Issue. Revolutionary improvements in heart failure (HF) treatment have been made in recent years. International heart failure guidelines advocate quadruple medical therapy in HF with reduced ejection fraction (HFrEF) and have been extended to HF with mildly reduced ejection fraction (HFmrEF). A new era in medical therapy for HF with preserved ejection fraction (HFpEF) has started with SGLT-2 inhibitors. However, implementation gaps exist and inertia in initiating new treatments is apparent. Approaches to the sequential initiation of the four foundational drugs are an area of ongoing debate. Treatment strategies for subgroups of HF patients that are underrepresented in clinical trials remain of significant importance. Further research focusing on the progress and challenges of implementing novel therapies in the real world and diverse HF patient populations would help to overcome this inertia. The aim of this Special Issue is to gather emerging data on approaches to novel HF therapies implementation worldwide and within different healthcare settings, efficacy and safety of combined HF therapies, embracing the diversity of HF patients and capturing a broader spectrum of end-points and outcomes.
We welcome articles on the following topics:
- Implementation of the foundational four therapies in HFrEF and HFmrEF in hospital and outpatient settings worldwide and implied related challenges including local healthcare delivery models, awareness of healthcare providers, and others.
- Real-world data on SGLT-2 inhibitors implementation in HFpEF
- Safety and efficacy of combined disease-modifying HF treatment in different subgroups of HF patients including elderly individuals, different ethnic groups, and gender, those suffering from advanced CKD and other comorbidities
- The effect of advanced HF therapies on functional status, symptoms, and quality of life.
- Mechanistic insight into the effects of disease-modifying HF therapy on cardiac structure and function, hemodynamics, and biomarkers.
- Additional potential beneficial effects of advanced HF therapy including cardiac rhythm, course of ischemia heart disease, congestion management, electrolyte disturbance, and hypertension among others.
We particularly encourage original research articles and meta-analyses. Please see the instructions for authors for submission requirements for each article type. To submit your article, please follow these instructions and select ‘Heart Failure’ as the Special Issue. All submitted articles will be subject to the journal's normal peer review process. Articles accepted for publication will be published upon acceptance. Visit our author hub for more information regarding the publication process for special issues. Key words: heart failure, foundational four pillars, quadruple therapy, real-world data, SGLT-2, ARNI, implementation, chronic kidney disease, biomarkers, myocardial remodelling, patient reported outcomes
Dr. Anastasia Shchendrygina I.M. Sechenov First Moscow State Medical University, Moscow, Russia orcid.org/0000-0002-8220-0350 Prof. Clara Ines Saldarriaga University of Antioquia Medellín, Colombia orcid.org/0000-0002-5945-1127